Morgan Dempsey Capital Management LLC Trims Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Morgan Dempsey Capital Management LLC trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 99.6% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 350 shares of the biopharmaceutical company’s stock after selling 85,386 shares during the period. Morgan Dempsey Capital Management LLC’s holdings in Gilead Sciences were worth $32,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. HHM Wealth Advisors LLC increased its position in shares of Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 154 shares during the last quarter. YANKCOM Partnership purchased a new stake in shares of Gilead Sciences during the 4th quarter valued at about $28,000. Decker Retirement Planning Inc. purchased a new stake in shares of Gilead Sciences during the 4th quarter valued at about $29,000. Crews Bank & Trust purchased a new stake in shares of Gilead Sciences during the 4th quarter valued at about $31,000. Finally, Stephens Consulting LLC increased its position in shares of Gilead Sciences by 325.0% during the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 260 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, February 12th. Wells Fargo & Company boosted their price target on Gilead Sciences from $105.00 to $120.00 and gave the company an “overweight” rating in a report on Wednesday, February 12th. Oppenheimer boosted their price target on Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a report on Tuesday, December 10th. Wolfe Research started coverage on Gilead Sciences in a report on Friday, November 15th. They set an “outperform” rating and a $110.00 price target for the company. Finally, BMO Capital Markets boosted their price target on Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a report on Wednesday, February 12th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the company. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $102.08.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the sale, the chief financial officer now directly owns 129,873 shares in the company, valued at $11,863,898.55. This represents a 1.89 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Insiders have sold a total of 293,356 shares of company stock worth $29,166,240 over the last ninety days. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $114.31 on Friday. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $114.77. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The business’s 50-day moving average is $97.42 and its 200 day moving average is $90.05. The company has a market capitalization of $142.46 billion, a P/E ratio of 308.95, a P/E/G ratio of 0.71 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be given a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a yield of 2.76%. Gilead Sciences’s dividend payout ratio is 854.05%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.